| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 33.19% | Keybanc | $37 → $25 | Maintains | Overweight |
| 07/07/2023 | 70.48% | Lake Street | → $32 | Reiterates | Buy → Buy |
| 07/06/2023 | 97.12% | Stephens & Co. | → $37 | Reiterates | Overweight → Overweight |
| 06/15/2023 | 59.83% | BTIG | $38 → $30 | Maintains | Buy |
| 06/07/2023 | 75.81% | Scotiabank | $54 → $33 | Maintains | Sector Outperform |
| 06/06/2023 | 113.11% | Canaccord Genuity | $60 → $40 | Maintains | Buy |
| 06/05/2023 | 86.47% | SVB Securities | $50 → $35 | Maintains | Outperform |
| 06/05/2023 | 70.48% | Lake Street | $41 → $32 | Maintains | Buy |
| 06/05/2023 | 33.19% | Baird | $35 → $25 | Maintains | Outperform |
| 05/08/2023 | 118.43% | Stephens & Co. | → $41 | Reiterates | → Overweight |
| 05/05/2023 | 97.12% | Keybanc | $40 → $37 | Maintains | Overweight |
| 05/04/2023 | 118.43% | Stephens & Co. | → $41 | Reiterates | → Overweight |
| 05/04/2023 | 86.47% | Baird | $38 → $35 | Maintains | Outperform |
| 03/02/2023 | 118.43% | Stephens & Co. | → $41 | Reiterates | → Overweight |
| 03/01/2023 | 102.45% | Baird | $42 → $38 | Maintains | Outperform |
| 01/05/2023 | 187.69% | Scotiabank | → $54 | Initiates Coverage On | → Sector Outperform |
| 11/03/2022 | 118.43% | Baird | $48 → $41 | Maintains | Outperform |
| 08/09/2022 | 155.73% | Baird | $44 → $48 | Maintains | Outperform |
| 08/09/2022 | 166.38% | SVB Leerink | $45 → $50 | Maintains | Market Outperform |
| 05/11/2022 | 113.11% | Keybanc | $90 → $40 | Maintains | Overweight |
| 05/10/2022 | 134.42% | Baird | $50 → $44 | Maintains | Outperform |
| 05/10/2022 | 139.74% | SVB Leerink | $65 → $45 | Maintains | Outperform |
| 04/05/2022 | 326.21% | Canaccord Genuity | $94 → $80 | Maintains | Buy |
| 03/01/2022 | 235.64% | Lake Street | $94 → $63 | Maintains | Buy |
| 01/07/2022 | 214.33% | Stephens & Co. | → $59 | Initiates Coverage On | → Overweight |
| 11/09/2021 | 299.57% | SVB Leerink | $85 → $75 | Maintains | Outperform |
| 07/14/2021 | 352.85% | SVB Leerink | $80 → $85 | Maintains | Outperform |
| 04/30/2021 | 400.8% | Lake Street | → $94 | Initiates Coverage On | → Buy |
| 02/03/2021 | 379.49% | Keybanc | $70 → $90 | Maintains | Overweight |
| 01/15/2021 | 326.21% | SVB Leerink | $70 → $80 | Maintains | Outperform |
| 12/11/2020 | 272.94% | SVB Leerink | $57 → $70 | Maintains | Outperform |
| 11/10/2020 | 272.94% | Keybanc | → $70 | Initiates Coverage On | → Overweight |
| 09/25/2020 | 203.68% | SVB Leerink | $50 → $57 | Maintains | Outperform |
| 08/11/2020 | 166.38% | SVB Leerink | $45 → $50 | Maintains | Outperform |
| 05/12/2020 | 139.74% | SVB Leerink | $40 → $45 | Maintains | Outperform |
| 03/27/2020 | 86.47% | Baird | $38 → $35 | Maintains | Outperform |
| 03/11/2020 | 102.45% | Baird | $37 → $38 | Maintains | Outperform |
| 12/27/2019 | 86.47% | Canaccord Genuity | $34 → $35 | Maintains | Buy |
| 09/04/2019 | 65.16% | Baird | $27 → $31 | Maintains | Outperform |
| 09/04/2019 | 81.14% | Canaccord Genuity | $26 → $34 | Maintains | Buy |
| 08/19/2019 | 33.19% | BTIG | → $25 | Initiates Coverage On | → Buy |
| 08/19/2019 | 38.52% | Canaccord Genuity | → $26 | Initiates Coverage On | → Buy |
| 08/19/2019 | 49.17% | SVB Leerink | → $28 | Initiates Coverage On | → Outperform |
| 08/19/2019 | 43.85% | Baird | → $27 | Initiates Coverage On | → Outperform |
What is the target price for Castle Biosciences (CSTL)?
The latest price target for Castle Biosciences (NASDAQ: CSTL) was reported by Keybanc on August 4, 2023. The analyst firm set a price target for $25.00 expecting CSTL to rise to within 12 months (a possible 33.19% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Castle Biosciences (CSTL)?
The latest analyst rating for Castle Biosciences (NASDAQ: CSTL) was provided by Keybanc, and Castle Biosciences maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Castle Biosciences (CSTL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Castle Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Castle Biosciences was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
Is the Analyst Rating Castle Biosciences (CSTL) correct?
While ratings are subjective and will change, the latest Castle Biosciences (CSTL) rating was a maintained with a price target of $37.00 to $25.00. The current price Castle Biosciences (CSTL) is trading at is $18.77, which is out of the analyst's predicted range.